November 25, 2016 - By Ellis Scott · 0 Comments
The stock of Axovant Sciences Limited (NYSE:AXON) registered an increase of 4.62% in short interest. AXON’s total short interest was 4.71M shares in November as published by FINRA. Its up 4.62% from 4.50 million shares, reported previously. With 204,000 shares average volume, it will take short sellers 23 days to cover their AXON’s short positions. The short interest to Axovant Sciences Limited’s float is 24.57%. The stock increased 4.98% or $0.67 on November 23, hitting $14.12. Axovant Sciences Ltd (NYSE:AXON) has risen 2.47% since April 22, 2016 and is uptrending. It has underperformed by 2.94% the S&P500.
Axovant Sciences Ltd., formerly Roivant Neurosciences Ltd., is a clinical-stage biopharmaceutical firm focused on acquiring, developing and commercializing therapeutics for the treatment of dementia. The company has a market cap of $1.47 billion. The Firm focuses on developing a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. It currently has negative earnings. The Company’s focus is to develop its lead product candidate, Intepirdine, which is a selective 5-hydroxytryptamine 6 receptor antagonist for the treatment of Alzheimer’s disease and dementia with Lewy bodies (DLB).
Out of 4 analysts covering Axovant Sciences (NYSE:AXON), 3 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 75% are positive. Axovant Sciences has been the topic of 4 analyst reports since September 25, 2015 according to StockzIntelligence Inc. The firm earned “Outperform” rating on Tuesday, June 7 by Leerink Swann. The rating was initiated by Piper Jaffray on Thursday, October 22 with “Overweight”. Chardan Capital Markets maintained it with “Sell” rating and $8 target price in Friday, September 25 report. The firm has “Buy” rating given on Friday, January 8 by H.C. Wainwright.
Axovant Sciences Ltd., formerly Roivant Neurosciences Ltd., incorporated on October 31, 2014, is a clinical-stage biopharmaceutical firm focused on acquiring, developing and commercializing therapeutics for the treatment of dementia. The Firm focuses on developing a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
More recent Axovant Sciences Ltd (NYSE:AXON) news were published by: Prnewswire.com which released: “Axovant Sciences to Present at Upcoming Investor Conferences” on September 26, 2016. Also Fool.com published the news titled: “Why Axovant Sciences Skyrocketed 56% in November” on December 03, 2015. Fool.com‘s news article titled: “Why Axovant Sciences Shares Are Crashing” with publication date: February 03, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Ellis Scott